Skip to main content
. 2017 Apr 13;3(4):483–491. doi: 10.1001/jamaoncol.2016.5478

Figure 2. Progression-Free Survival and Overall Survival by KRAS Genotype and p16 Status for Patients Treated Without or With Cetuximab Treatment.

Figure 2.

A, Progression-free survival. There is a significant 2-way interaction between KRAS-variant status and p16 in patients treated without cetuximab (P = .04). B, Overall survival. There is a significant 3-way interaction among cetuximab treatment, KRAS-variant status, and p16 status (P = .02).